Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome

Summary

We will identify the influence of long-term treatment of Pitavastatin compared to non-treatment control group on the metabolic syndrome by evaluation of a change of metabolic syndrome component score. And we will additionally observe the changes of CVD risk factors like lipid profile, abdominal fat, insulin resistance and so on.

Timeline

Start

2008-04

Primary completion

2011-02

Completion

2011-06

Drugs

Indications